Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aspirin Strategy Group calls for advisory committee review of new aspirin indications.

This article was originally published in The Tan Sheet

Executive Summary

ASPIRIN PROFESSIONAL INDICATIONS REVIEW BY FDA ADVISORY COMMITTEE URGED by Charles Hennekens, MD/PhD, Harvard Medi-cal School, in a July 18 letter to OTC Drug Division Director Debra Bowen, MD. The letter asserts that "a meeting of the Cardiovascular and Renal Drugs Advisory Committee should be scheduled as expeditiously as possible to make recommendations concerning any additional cardiovascular uses of aspirin that are justified."
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS085936

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel